This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mückter, H. Articles by Moré, E. Search for Related Content PubMed PubMed Citation Articles by Mückter, H. Articles by Moré, E.

Experimental Therapeutic Investigations with 1-(Morpholinomethyl)-4-phthalimido-piperidindione-2,6 on Dimethylbenzanthracene-induced Tumors of Sprague-Dawley Rats

Research Laboratories, Chemie Grinenthal GmbH., Stolberg/Rheinland, Germany

1-(Morpholinomethyl)-4-phthalimido-piperidindione-2,6 (CG 603) had a greater therapeutic effect than bilateral ovariectomy, estrogen (mestranol, 17-ethinylestradiol-3-methylether), or androgen (drostanolone propionate, 2-methyldihydrotestosterone propionate, 2-MDTP) on 7,12-dimethylbenzanthracene-induced tumors in Sprague-Dawley rats. The antitumor activity of CG 603 was equivalent to hypophysectomy. Combined treatment with CG 603 and ovariectomy or estrogen gave no significant increase in antitumor activity over that with CG 603 alone. The combined treatment with CG 603 and 2-MDTP showed a significantly higher regression of tumor weight and tumor number than the treatment with CG 603 or 2-MDTP alone. While CG 603 in higher concentrations decreases the body weight of experimental animals, the combination of CG 603 in lower concentration with the anabolically acting 2-MDTP increases the body weight of the treated animals. CG 603 probably exerts its antitumor activity primarily via endocrine pathways, and this is supported by endocrinologic studies.

Received 3/20/67. Accepted 1/ 3/69.